6.
Suwala A, Stichel D, Schrimpf D, Kloor M, Wefers A, Reinhardt A
. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol. 2020; 141(1):85-100.
PMC: 7785563.
DOI: 10.1007/s00401-020-02243-6.
View
7.
Price M, Ryan K, Shoaf M, Neff C, Iorgulescu J, Landi D
. Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015-2019. Neurooncol Pract. 2024; 11(1):5-25.
PMC: 10785588.
DOI: 10.1093/nop/npad061.
View
8.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A
. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118(4):469-74.
DOI: 10.1007/s00401-009-0561-9.
View
9.
Parkes J, Hendricks M, Ssenyonga P, Mugamba J, Molyneux E, Schouten-van Meeteren A
. SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings. Pediatr Blood Cancer. 2014; 62(4):553-64.
DOI: 10.1002/pbc.25313.
View
10.
Price M, Neff C, Nagarajan N, Kruchko C, Waite K, Cioffi G
. CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2024; 26(Supplement_3):iii1-iii53.
PMC: 11073545.
DOI: 10.1093/neuonc/noae047.
View
11.
Cavalli F, Remke M, Rampasek L, Peacock J, Shih D, Luu B
. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017; 31(6):737-754.e6.
PMC: 6163053.
DOI: 10.1016/j.ccell.2017.05.005.
View
12.
Leblond P, Massimino M, English M, Ritzmann T, Gandola L, Calaminus G
. Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol. Front Neurol. 2022; 13:887544.
PMC: 9201444.
DOI: 10.3389/fneur.2022.887544.
View
13.
Gururangan S, Fangusaro J, Poussaint T, McLendon R, Onar-Thomas A, Wu S
. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2013; 16(2):310-7.
PMC: 3895377.
DOI: 10.1093/neuonc/not154.
View
14.
Meyronet D, Esteban-Mader M, Bonnet C, Joly M, Uro-Coste E, Amiel-Benouaich A
. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol. 2017; 19(8):1127-1134.
PMC: 5570304.
DOI: 10.1093/neuonc/now274.
View
15.
Bouffet E, Hansford J, Garre M, Hara J, Plant-Fox A, Aerts I
. Dabrafenib plus Trametinib in Pediatric Glioma with V600 Mutations. N Engl J Med. 2023; 389(12):1108-1120.
DOI: 10.1056/NEJMoa2303815.
View
16.
Calaminus G, Kortmann R, Worch J, Nicholson J, Alapetite C, Garre M
. SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation.... Neuro Oncol. 2013; 15(6):788-96.
PMC: 3661100.
DOI: 10.1093/neuonc/not019.
View
17.
Rudin C, Hann C, Laterra J, Yauch R, Callahan C, Fu L
. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009; 361(12):1173-8.
PMC: 5317279.
DOI: 10.1056/NEJMoa0902903.
View
18.
Fangusaro J, Onar-Thomas A, Poussaint T, Wu S, Ligon A, Lindeman N
. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019; 20(7):1011-1022.
PMC: 6628202.
DOI: 10.1016/S1470-2045(19)30277-3.
View
19.
Giordana M, Schiffer P, Lanotte M, Girardi P, Chio A
. Epidemiology of adult medulloblastoma. Int J Cancer. 1999; 80(5):689-92.
DOI: 10.1002/(sici)1097-0215(19990301)80:5<689::aid-ijc10>3.0.co;2-g.
View
20.
Ostrom Q, Price M, Neff C, Cioffi G, Waite K, Kruchko C
. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2023; 25(12 Suppl 2):iv1-iv99.
PMC: 10550277.
DOI: 10.1093/neuonc/noad149.
View